Stryker Corp. (SYK) shares rallied 5.25% to close at $332.71 on Friday, marking a strong performance despite a broader market decline where the S&P 500 fell 0.05% and the Dow Jones Industrial Average dropped 0.09%. This positive move occurred in an environment characterized by an all-around rough trading session for the general stock market.
The rally represents the fourth consecutive day of gains for Stryker Corp., highlighting a sustained period of outperformance relative to its competitors and the wider index. While the article does not detail specific earnings or operational drivers, the consistent upward momentum suggests strong investor confidence in the company's immediate trajectory.
📈 SYK shares rallied 5.25% to $332.71 on Friday.
🚀 Stock posted fourth consecutive day of gains.
📉 Rally occurred while S&P 500 and Dow fell.
🏆 Company outperformed competitors during market decline.
📈 Stryker Corp. (SYK) shares rallied 5.25% to $332.71 on Friday.
🚀 This was the fourth consecutive day of gains for the stock.
📉 The rally occurred while the broader market declined, with the S&P 500 falling 0.05% and the Dow Jones dropping 0.09%.
🏆 Stryker Corp. outperformed competitors during this rough trading session.
Bullish Signals
- Shares gained 5.25% to close at $332.71.
- Stock posted gains for four consecutive days.
Bullish Signals
- SYK shares gained 5.25% to close at $332.71, demonstrating significant strength relative to the broader market decline.
- The stock has posted gains for four consecutive days, indicating sustained positive momentum and investor interest.
Stryker (SYK) has received positive attention following a federal court ruling in its favor regarding an OptaBlate patent dispute. This legal victory alleviates concerns over the company's intellectual property as it simultaneously advances new surgical products and increases adoption of its Mako robotics platform.
Despite these developments, Stryker's short-term share price momentum has weakened, with the stock down 12.49% year-to-date and an 18.87% decline in total shareholder return over the past year. However, longer-term returns remain resilient, showing a 5.67% gain over three years and a 23.23% gain over five years.
Analysts suggest Stryker could be undervalued by approximately 21.2%, with a calculated fair value of $386.80 compared to the recent closing price of $304.69. The company's robust innovation pipeline in robotic-assisted surgery is expected to drive market share growth, higher average selling prices, and margin expansion over time.
Valuation metrics present mixed signals; while cash flow models indicate undervaluation, Stryker trades at a 35x P/E ratio, which is significantly higher than the peer average of 28x. Investors must weigh the potential for future growth against risks such as regulatory delays and margin pressures from inflation or tariffs.
🏛️ Stryker wins favorable patent ruling easing legal risks.
🤖 Mako robotics adoption drives new surgical product traction.
📉 Stock down 12.49% YTD but resilient over five years.
💰 Analysts see 21.2% undervaluation with $386.80 fair value.
🚀 Innovation pipeline expected to boost market share and margins.
🏛️ Stryker secured a favorable federal court ruling in its OptaBlate patent dispute, easing legal concerns.
🤖 The company is gaining traction with new surgical products and increased adoption of its Mako robotics platform.
📉 Short-term stock momentum has softened, with shares down 12.49% year-to-date and an 18.87% total return decline over the last year.
📈 Longer-term performance remains resilient, with 5-year total shareholder returns of 23.23%.
💰 Analysts estimate a fair value of $386.80 against a recent close of $304.69, suggesting a potential 21.2% undervaluation.
🚀 A robust innovation pipeline in robotic-assisted surgery is expected to drive market share and margin expansion.
⚖️ Stryker trades at a 35x P/E ratio, which is higher than the peer average of 28x and a calculated fair ratio of 31x.
🛡️ The company maintains a solid track record with an adequate balance sheet and pays a dividend.
Bullish Signals
- Stryker won key federal court ruling on OptaBlate patent dispute.
- Successfully advancing new surgical products with increased Mako robotics adoption.
- Analysts calculate fair value of $386.80 vs current price of $304.69.
- 23.23% total return over past five years despite recent weakness.
- Innovation pipeline expected to drive higher market share and selling prices.
Risk Factors
- 12.49% share price decline year-to-date.
- 35x P/E premium versus 28x peer average.
- Growth relies on regulatory approvals facing delays.
- Inflation and tariffs risk squeezing margins.
Bullish Signals
- Stryker won a key federal court ruling in its OptaBlate patent dispute, removing a significant legal overhang.
- The company is successfully advancing new surgical products and seeing increased adoption of its Mako robotics platform.
- Analysts calculate a fair value of $386.80 versus the current price of $304.69, implying the stock is undervalued by 21.2%.
- Long-term shareholder returns are strong, with a 23.23% total return over the past five years despite recent weakness.
- The innovation pipeline in robotic-assisted surgery is expected to drive higher market share and average selling prices.
Risk Factors
- Stryker's short-term share price momentum has softened significantly, with a 12.49% decline year-to-date.
- The stock trades at a premium P/E of 35x compared to the peer average of 28x, suggesting high valuation expectations.
- Future growth assumptions rely on regulatory approvals that could face delays.
- Inflation and tariff pressures pose a risk of squeezing margins and earnings power.
Stryker Corporation (SYK) is a global medical technology leader with a market cap of $118.4 billion, operating in Orthopaedics, MedSurg, and Neurotechnology. Despite facing an unexpected cyber disruption that impacted first-quarter results, the company maintains strong underlying demand, a robust capital order book, and significant international momentum. Management emphasizes that organic sales growth was constrained by shipment delays rather than weakening customer demand.
The article highlights Stryker's strategic advantages in its robotics ecosystem, particularly the Mako platform, which saw record installations and increasing utilization rates globally. The company is expanding this ecosystem with new handheld solutions and advanced hip revision procedures to strengthen its competitive moat. International markets, including Japan, Europe, India, and the Middle East, are emerging as major growth engines with significant room for market share expansion.
However, Stryker faces several headwinds including margin pressures from tariffs, inflation, and lost manufacturing absorption following the cyberattack. The company also takes on execution risks by expanding into newer categories like cardiovascular technologies and AI-enabled solutions, which adds operational complexity. Analysts note a positive estimate revision trend for 2026, with earnings expected to improve 10.6% over the next five years.
Zacks Investment Research maintains a 'Hold' rating (Rank #3) on SYK, noting its shares have underperformed the industry and S&P 500 year-to-date despite solid fundamentals. The consensus estimate for second-quarter 2026 revenues is pegged at $6.56 billion, implying an 11.5% bottom-line growth. While the cyberattack exposes operational vulnerabilities, management has successfully restored systems and reaffirmed full-year guidance.
📈 SYK shares down 13.1% YTD vs industry's 23.1% decline.
💻 Cyberattack caused 190 basis point adjusted gross margin drop.
🤖 Mako robotics platform achieved record global installations and growth.
🌍 International markets in Japan, Europe, India drive major expansion.
⚠️ Tariffs and input costs threaten future margin improvement goals.
📈 Stryker (SYK) holds a Zacks Rank #3 (Hold) with shares down 13.1% YTD versus the industry's 23.1% decline.
💻 A recent cyberattack disrupted Q1 manufacturing and revenue recognition, causing adjusted gross margin to decline 190 basis points.
🤖 The Mako robotics platform achieved record installations globally with increasing utilization rates and new handheld solutions launching.
🌍 International operations are becoming a major growth engine with strong momentum in Japan, Europe, India, and the Middle East.
💰 Management expects SYK's bottom line to improve 10.6% over the next five years despite current margin pressures.
📉 Q2 2026 revenue consensus is pegged at $6.56 billion, implying an 11.5% year-over-year growth in earnings.
⚠️ Margin expansion faces headwinds from tariffs, rising input costs, freight expenses, and geopolitical developments.
🔬 Expansion into peripheral vascular intervention and AI-enabled hospital solutions adds execution complexity and regulatory uncertainty.
🛡️ Management successfully restored manufacturing systems after the cyberattack but warns of future cybersecurity threats.
📊 The company has a market capitalization of $118.4 billion and operates across Orthopaedics, MedSurg, and Neurotechnology.
Bullish Signals
- Healthy demand and elevated order book ensure future revenue visibility.
- Record Mako installations prove a strong competitive moat in robotics.
- International expansion opportunities exist in Japan, Europe, India, and Middle East.
- SYK beat earnings estimates for four quarters with minimal surprise.
- New Mako RPS product broadens surgical access globally.
- Management reaffirmed full-year guidance despite recent cyberattack disruptions.
- 2026 consensus estimates show 10.6% expected earnings growth over five years.
Risk Factors
- Cyberattack reduced Q1 profitability and disrupted shipments.
- Q1 adjusted gross margin declined 190 basis points.
- Operating margin fell 180 basis points due to tariffs.
- New category expansion increases execution risk and capital uncertainty.
- Future cybersecurity threats remain a material operational risk.
Bullish Signals
- Underlying demand remains healthy with an elevated capital equipment order book providing solid visibility into future revenue.
- Record Mako installations and increasing utilization rates demonstrate a powerful competitive moat in the robotics ecosystem.
- International markets offer ample room for expansion, particularly in Japan, Europe, India, and emerging Middle Eastern regions.
- SYK has beaten earnings estimates in each of the trailing four quarters with an average negative surprise of only 1.82%.
- The company is launching new products like Mako RPS handheld robotic solution to broaden access for surgeons.
- Management reaffirmed full-year guidance despite operational disruptions caused by the recent cyberattack.
- Consensus estimates for 2026 show a positive revision trend with earnings expected to increase 10.6% over five years.
Risk Factors
- The cyberattack disrupted manufacturing and shipments, reducing Q1 profitability and highlighting dependence on digital infrastructure.
- First-quarter adjusted gross margin declined 190 basis points and operating margin fell 180 basis points due to lost absorption and tariffs.
- Expansion into new categories like cardiovascular technologies increases execution risk and capital investment uncertainty.
- Future cybersecurity threats remain a material risk given the increasingly digital nature of healthcare operations.
- Tariff uncertainty could limit earnings growth even if revenue recovery proceeds according to plan.
Worldwide Healthcare Trust PLC reported that AstraZeneca PLC was its top contributor to portfolio performance for the financial year ended March 31, with net asset value per share reaching 371.0 pence, a 9.3% increase from the prior year's 339.5 pence. The trust achieved a NAV total return of 10.0%, significantly outperforming its MSCI World Health Care index benchmark which returned just 1.8%. AstraZeneca was highlighted as the premier global diversified pharmaceutical player with leading franchises in oncology, respiratory, rare disease, and cardiovascular disease, supported by a portfolio of 16 distinct blockbuster medicines and numerous phase 3 clinical trials.
Conversely, surgical equipment firm Stryker Corp served as the top detractor due to macro rotation out of MedTech stocks and investor skepticism regarding volume growth, despite a fourth quarter net sales increase of 11.4%. Other notable contributors included GC Oncology, Exact Sciences, Avidity Biosciences, and Apellis Pharmaceutical, while Vertex Pharmaceuticals, Daiichi Sankyo, UnitedHealth Group, and Boston Scientific were among the top detractors. The trust's chair, Doug McCutcheon, noted that merger and acquisition activity was a meaningful contributor to performance and expressed a positive long-term outlook for global equities and the healthcare sector, citing supportive US regulatory environments and attractive valuations in biotechnology.
📈 NAV rose 9.3% to 371.0 pence, outperforming the benchmark by 8.2%.
💊 AstraZeneca led gains while Stryker dragged performance down due to rotation.
🔄 Doug McCutcheon retires as Chair; William Hemmings will succeed him.
📈 Worldwide Healthcare Trust reported a net asset value per share of 371.0 pence as of March 31, representing a 9.3% increase from the previous year.
📊 The fund achieved a NAV total return of 10.0% for the financial year ended March 31, significantly outperforming its MSCI World Health Care index benchmark which returned just 1.8%.
💊 AstraZeneca PLC was identified as the top contributor to portfolio performance, with the London-based pharma giant being the only Europe-based company in the fund's top five contributors.
🔬 Management praised AstraZeneca for solidifying its status as a premier global player with leading franchises in oncology, respiratory, rare disease, and cardiovascular disease.
⚠️ Stryker Corp was the top detractor from performance, pressured by a macro rotation out of MedTech stocks and investor skepticism regarding volume growth despite an 11.4% net sales increase in Q4.
🔍 Other notable detractors included Vertex Pharmaceuticals Inc, Tokyo-based Daiichi Sankyo Co Ltd, UnitedHealth Group Inc, and Boston Scientific Corp.
🤝 Merger and acquisition activity was cited as a meaningful contributor to the fund's overall performance during the reported period.
🌐 The firm noted that US healthcare policy uncertainty lifted late in 2025, leading biotechnology and pharmaceutical sub-sectors to begin outperforming.
👴 Doug McCutcheon, the current Chair of Worldwide Healthcare, announced he will retire after the company's annual general meeting on July 14.
🔄 William Hemmings is set to succeed Doug McCutcheon as the new Chair following his retirement at the upcoming AGM.
📉 Shares in Worldwide Healthcare were trading 0.3% higher at 346.88 pence each on Friday morning in London.
🌍 The portfolio manager and board remain positive on the long-term outlook for global equities, particularly within the global healthcare sector.
💰 Large cap pharmaceutical companies are facing patent expiry pressures, prompting heavy investment in innovative pipelines and continued M&A activity in biotechnology.
📉 The fund's benchmark is the MSCI World Health Care index on a net total return sterling adjusted basis.
🏥 The top five contributors included GC Oncology, Exact Sciences, Avidity Biosciences, and Apellis Pharmaceutical alongside AstraZeneca.
Bullish Signals
- NAV per share rose 9.3% to 371.0 pence.
- Fund NAV return of 10.0% beat benchmark by 8.2%.
- AstraZeneca led performance with strong oncology and respiratory franchises.
- Portfolio includes 16 blockbuster medicines and active phase 3 trials.
- M&A activity significantly boosted overall fund performance.
Risk Factors
- Stryker Corp faces volume skepticism despite 11.4% Q4 sales growth.
- MedTech sector vulnerable to rotation and Boston Scientific sentiment shifts.
- Large cap pharma pressured by patent expiries forcing pipeline investment.
Bullish Signals
- Worldwide Healthcare Trust's net asset value per share reached 371.0 pence as of March 31, representing a strong 9.3% increase from the previous year.
- The fund delivered a NAV total return of 10.0% for the financial year ended March 31, significantly outperforming its benchmark MSCI World Health Care index which returned only 1.8%.
- AstraZeneca was identified as the top contributor to portfolio performance, solidifying its status with leading franchises in oncology, respiratory, rare disease, and cardiovascular disease.
- The company highlighted an impressive breadth of innovation including a plethora of announced phase 3 clinical trials and a portfolio of 16 distinct blockbuster medicines.
- Merger & acquisition activity was noted as a meaningful contributor to the fund's overall performance.
- US healthcare policy uncertainty lifted late in 2025, leading biotechnology and pharmaceutical sub-sectors to begin outperforming.
- The board remains positive on the long-run outlook for global equities and specifically for the global healthcare sector.
- Large cap pharmaceutical companies are investing heavily in innovative pipelines due to patent expiry pressures, creating a strong incentive for continued M&A activity in the biotechnology sector where valuations remain attractive.
Risk Factors
- Stryker Corp was identified as the top detractor in the portfolio due to investor skepticism regarding volume growth, despite a reported fourth quarter net sales increase of 11.4%.
- The stock pressure on Stryker was exacerbated by macro rotation out of MedTech stocks and the 'Boston Scientific Effect', highlighting the sector's vulnerability to sudden shifts in investor sentiment regarding hospital capital expenditures.
- Doug McCutcheon noted that large cap pharmaceutical companies continue to face significant patent expiry pressures, which forces them to invest heavily in innovative pipelines.
Stryker Corp (NYSE: SYK) director Ronda E Stryker executed a significant insider sell on May 28, disposing of 310,000 shares valued at $96.79 million according to an SEC Form 4 filing submitted Thursday. This transaction represents a substantial reduction in equity but is one of many factors investors must consider alongside the broader financial landscape surrounding the medical device leader.
The article provides detailed context on Stryker's current financial metrics, noting a revenue growth rate of approximately 2.63% for the period ending March 31, 2026, though this trails its industry peers in the Health Care sector. The company maintains a debt-to-equity ratio of 0.64, which is higher than the industry average, suggesting a greater reliance on borrowed funds compared to competitors. Conversely, Stryker boasts a robust market position with a gross margin of 63.29% and earnings per share significantly outperforming industry norms.
Valuation analysis indicates mixed signals regarding stock price relative to fundamentals; the company trades at a P/E ratio of 35.61, which is below industry norms suggesting potential undervaluation, yet its Price-to-Sales ratio of 4.71 and high EV/EBITDA of 20.14 suggest elevated valuations based on sales and enterprise value metrics. Roughly one-fourth of Stryker's revenue currently originates from international markets outside the United States, highlighting its global exposure in reconstructive orthopedic implants and operating room equipment where it holds a leadership position.
📉 Director Ronda E Stryker sold $96.8M worth of shares on May 28.
📈 Stock rose 0.34% to $308.67 with 2.63% revenue growth in Q1 2026.
⚠️ Revenue lags peers while debt-to-equity (0.64) exceeds industry averages.
💰 High gross margin of 63.29% and EPS of $1.95 outperform competitors.
🌍 One-fourth of revenue comes from international markets outside the US.
📉 Director Ronda E Stryker sold 310,000 shares of Stryker (NYSE: SYK) on May 28, according to an SEC Form 4 filing.
💰 The total value of the insider sale was $96,792,668 at the time of execution.
📈 Stryker's stock is trading at $308.67 and rose 0.34% during Friday's morning session.
📊 Over a three-month period ending March 31, 2026, the company reported revenue growth of approximately 2.63%.
⚠️ This revenue growth rate trails behind the average among peers in the Health Care sector.
💳 Stryker's debt-to-equity ratio stands at 0.64, which is notably higher than the industry average.
🏢 The company maintains a market capitalization that surpasses industry standards, indicating a robust market position.
📝 Insider transactions are legally required to be disclosed via Form 4 filings within two business days of the trade.
🤔 Insider sales do not necessarily signal a bearish stance and can be motivated by various personal or financial factors.
🦴 Stryker designs and markets medical equipment including hip and knee replacements, orthopedic robotics, and operating room equipment.
🌍 Roughly one-fourth of Stryker's total revenue currently comes from outside the United States.
💵 The company boasts a high gross margin of 63.29%, reflecting superior cost management compared to peers.
📉 Current earnings per share (EPS) is $1.95, which is significantly higher than the industry average.
📈 The current P/E ratio of 35.61 is below industry norms, suggesting potential undervaluation.
📉 Conversely, the P/S ratio of 4.71 is above industry norms, reflecting an elevated valuation based on sales performance.
🔢 A high EV/EBITDA ratio of 20.14 positions the company as more valued compared to industry benchmarks.
📊 Transaction codes in Form 4 filings use 'S' for sales, 'P' for purchases, and 'C' for option conversions.
🏛️ Under Section 12 of the Securities Exchange Act of 1934, insiders include officers, directors, or beneficial owners holding more than ten percent of equity.
Bullish Signals
- Stryker shares gained 0.34% at $308.67.
- Revenue grew 2.63% by March 2026.
- Gross margin stands high at 63.29%.
- EPS of $1.95 exceeds industry average.
- P/E ratio of 35.61 suggests undervaluation.
- Leader in orthopedic implants and OR equipment.
- International revenue comprises roughly one-fourth.
Risk Factors
- Director sold $96.79M shares, signaling potential stock concerns.
- Revenue growth of 2.63% trails Health Care sector peers.
- Debt-to-equity ratio of 0.64 exceeds industry averages.
- P/S ratio of 4.71 indicates elevated valuation risk.
- EV/EBITDA of 20.14 suggests potential overvaluation.
Bullish Signals
- Stryker's shares are actively trading at $308.67, experiencing a gain of 0.34% during Friday's morning session.
- The company achieved a revenue growth rate of approximately 2.63% as of March 31, 2026, indicating a substantial increase in top-line earnings.
- Stryker maintains a high gross margin of 63.29%, reflecting superior cost management and profitability compared to its peers.
- The company demonstrates robust bottom-line performance with a current EPS of $1.95, which is significantly higher than the industry average.
- With a P/E ratio of 35.61, Stryker's valuation is below industry norms, indicating potential undervaluation and presenting an investment opportunity.
- Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment.
- Roughly one-fourth of Stryker's total revenue currently comes from outside the United States, demonstrating strong international market presence.
Risk Factors
- Director Ronda E Stryker executed a substantial insider sell of $96.79M worth of shares on May 28, which may signal concerns about future stock performance despite management's stated neutrality.
- Stryker's revenue growth rate of approximately 2.63% trails behind the average among peers in the Health Care sector, indicating slower top-line expansion relative to competitors.
- The company's debt-to-equity ratio stands at 0.64, which is notably higher than the industry average and raises concerns about financial leverage and reliance on borrowed funds.
- Stryker's current P/S ratio of 4.71 is above industry norms, reflecting an elevated valuation that could present downside risk if sales growth does not accelerate to justify the premium.
- The company's EV/EBITDA ratio of 20.14 positions it as more valued compared to industry benchmarks, suggesting potential overvaluation relative to earnings power.
Stryker Corporation (NYSE: SYK) announced the European launch of its Pangea Plating System, a new non-active implant platform designed for fracture fixation across the upper and lower extremities. The system combines thoughtfully designed plates with a streamlined instrumentation set to offer surgeons practical options for treating various fracture patterns while maintaining simplicity in the operating room.
The product was developed in collaboration with 26 orthopaedic surgeons globally, incorporating anatomical data to ensure proper plate fit across diverse patient populations. A key feature of the Pangea system is its variable-angle plating design, which allows for flexible screw placement angles to improve surgical fit and healing outcomes without adding unnecessary complexity.
Prof. Alex Trompeter of St. George's University Hospital in London completed the first clinical case in Europe with the new system. Industry experts, including Dr. Arvind von Keudell from Harvard Medical School, praised the device for supporting consistent workflows and helping surgeons adapt to different fracture patterns effectively.
🚀 Stryker launches Pangea Plating System in Europe for fractures.
👥 Platform developed with 26 global orthopaedic surgeons.
🔧 Features variable-angle plating for flexible screw placement.
🏥 Prof. Alex Trompeter performs first European clinical case.
💡 Non-active implants simplify operating room workflows.
🚀 Stryker launches the Pangea Plating System in Europe for treating a wide range of fracture patterns.
👥 The platform was developed through collaboration with 26 orthopaedic surgeons from around the world.
🔧 The system features variable-angle plating to allow flexible screw placement for improved surgical fit.
🏥 Prof. Alex Trompeter completed the first clinical case in Europe at St. George's University Hospital.
💡 The non-active implants are designed to provide temporary stabilization with simplified operating room workflows.
🌍 The launch expands access to Stryker's trauma portfolio and reflects a focus on evolving trauma care needs.
Bullish Signals
- Variable-angle plating improves fit and reduces complications.
- Data from 26 surgeons supports diverse patient fits.
- Expands Stryker's European trauma market access.
Bullish Signals
- The Pangea Plating System is designed to simplify fracture surgery by combining thoughtfully designed plates with a streamlined instrumentation set.
- Variable-angle plating technology offers flexibility in screw placement, which can improve surgical fit and potentially reduce complication rates.
- The system incorporates global anatomical data collected from 26 surgeons to support plate fit across diverse patient populations.
- Industry leaders highlight the device's ability to support consistent workflows while offering adaptability for different fracture patterns.
- The European launch expands market access for Stryker's trauma portfolio and reinforces its commitment to developing solutions that enhance surgical efficiency.
Fisher Asset Management LLC reduced its stake in Stryker Corporation (NYSE: SYK) by 5.8% during the fourth quarter, selling 192,839 shares and retaining a position valued at approximately $1.10 billion. This move coincides with Stryker's recent quarterly earnings miss, where the company reported EPS of $2.60 against expectations of $2.98 and revenue of $6.02 billion versus an estimated $6.34 billion, despite a 2.6% year-over-year revenue increase.
Analyst sentiment has shifted toward caution following the earnings miss, with several major firms lowering price targets or downgrading ratings. UBS cut its target to $380 with a neutral rating, while TD Cowen and Goldman Sachs also issued neutral or hold ratings. Despite these headwinds, the stock maintains a 'Moderate Buy' consensus with an average price target of $395.48, though recent downgrades suggest growing skepticism among Wall Street analysts.
Institutional ownership remains robust, with Vanguard increasing its stake by 0.4% and AllianceBernstein raising theirs by 13.3%. However, insider activity presents a mixed signal; while major funds are accumulating, Stryker VP M Kathryn Fink sold 95.19% of her holdings for nearly $1 million in May. The company also declared a quarterly dividend of $0.88 per share, payable on July 31st to shareholders of record on June 30th.
📉 Fisher Asset Management trimmed Stryker position by 5.8% in Q4.
💰 Stryker missed Q4 EPS and revenue estimates despite growth.
📊 Major banks issued neutral or hold ratings after earnings miss.
🏦 Vanguard and AllianceBernstein increased stakes showing long-term confidence.
💸 VP Kathryn Fink sold nearly all shares signaling insider caution.
📉 Fisher Asset Management trimmed its Stryker position by 5.8% in Q4, selling 192,839 shares while retaining a $1.10 billion stake.
💰 Stryker reported Q4 EPS of $2.60 and revenue of $6.02 billion, missing analyst estimates for both metrics despite positive YoY revenue growth.
📊 Analyst consensus has weakened with UBS, TD Cowen, and Goldman Sachs issuing neutral or hold ratings following the earnings miss.
🏦 Major institutional investors like Vanguard and AllianceBernstein increased their stakes, indicating continued long-term confidence.
💸 VP M Kathryn Fink sold 95.19% of her shares for $992,075 in a May transaction, signaling insider caution.
📈 The stock trades at a PE ratio of 36.62 with a market cap of $121.29 billion and a current price near $316.
💵 Stryker declared a quarterly dividend of $0.88 per share, offering a yield of 1.1% to eligible investors.
🔮 The company provided FY 2026 EPS guidance ranging between $14.90 and $15.10.
Bullish Signals
- Vanguard increased stake to 33.9 million shares.
- Alliancebernstein raised position by 13.3% adding 741k shares.
- Revenue grew 2.6% year-over-year to $6.02 billion.
- Current ratio of 2.11 and debt-to-equity of 0.62.
- Quarterly dividend of $0.88 per share with 1.1% yield.
Risk Factors
- Missed EPS ($2.60 vs $2.98) and revenue ($6.02B vs $6.34B).
- Analysts downgraded stock; UBS target cut to $380.
- VP sold 95.19% holdings for nearly $1 million.
- Trading below 50-day ($325.22) and 200-day ($349.76) averages.
Bullish Signals
- Vanguard Group Inc. increased its stake in Stryker by 0.4% to own over 33.9 million shares, demonstrating strong institutional confidence.
- Alliancebernstein L.P. significantly raised its position by 13.3% in the third quarter, adding over 741,000 shares to its portfolio.
- Stryker achieved a 2.6% year-over-year revenue increase to $6.02 billion, showing underlying business growth despite missing earnings estimates.
- The company maintains healthy financial metrics with a current ratio of 2.11 and a debt-to-equity ratio of only 0.62.
- Stryker declared a quarterly dividend of $0.88 per share, providing a 1.1% yield to shareholders of record on June 30th.
Risk Factors
- Stryker missed analyst expectations for both EPS ($2.60 vs $2.98) and revenue ($6.02B vs $6.34B) in the most recent quarter.
- Several major analysts have downgraded the stock or lowered price targets, including UBS cutting its target to $380 with a neutral rating.
- VP M Kathryn Fink sold 95.19% of her personal holdings for nearly $1 million, indicating significant insider selling activity.
- The stock is trading below its 50-day ($325.22) and 200-day ($349.76) moving averages, suggesting short-term weakness.
Truist lowered its price target for Stryker Corporation (NYSE:SYK) from $380 to $330 while maintaining a Hold rating following updates to its financial model after the medical technology company's first-quarter results. The reduction reflects disruptions caused by a cyber-related incident that affected earnings timing and flow, alongside broader valuation pressure in the large-cap medical technology sector which has reduced multiples across peers. Despite this analyst downgrade, Stryker reaffirmed on April 30 its fiscal 2026 outlook with adjusted earnings per share guidance between $14.90 and $15.10, slightly above consensus expectations. The company also projected organic net sales growth of 8.0% to 9.5%, supported by modestly positive pricing trends and a slight foreign exchange tailwind assuming current currency levels persist.
Stryker is based in Portage, Michigan, and develops products in orthopaedics, surgical equipment, and neurotechnology for patients worldwide. While the article notes certain AI stocks may offer greater upside potential or benefit from tariffs during the Trump era, these recommendations are tangential to the core analysis of Stryker's current market position and financial guidance. The cyber incident remains a key factor influencing the short-term outlook, as investors await clarity on operational recovery and earnings normalization alongside industry-wide valuation adjustments.
📉 Truist cut Stryker price target to $330 due to valuation pressure and a Q1 cyber incident.
🏭 Company reaffirmed FY26 EPS guidance of $14.90-$15.10 with expected 8-9.5% organic sales growth.
⚖️ Analysts maintain Hold ratings, though some favor AI stocks over Stryker for better upside.
📉 Truist lowered its Stryker (SYK) price target from $380 to $330, citing valuation pressure.
⚖️ Analysts maintain a Hold rating on the stock despite the price target reduction.
💻 A cyber-related incident in Q1 affected earnings timing and flow, influencing the outlook adjustment.
📊 The firm updated its financial model based on first quarter results before making the revision.
🌍 Broader valuation pressure across large-cap medical technology peers contributed to the lower outlook.
🏭 Stryker reaffirmed fiscal 2026 earnings per share guidance of $14.90 to $15.10, above consensus.
💹 The company expects organic net sales growth between 8.0% and 9.5%, supported by pricing trends.
💵 Foreign exchange is projected to provide a slight tailwind to revenue and adjusted earnings per share.
🏥 Stryker is a global medical technology company based in Portage specializing in orthopaedics, surgical equipment, and neurotechnology.
🤖 Analysts suggest AI stocks may offer greater upside potential compared to SYK currently.
📜 The article notes no specific disclosure was provided regarding the authors' positions or transactions.
Risk Factors
- Truist lowered SYK price target $380 to $330 due to valuation pressure.
- Cyber incident in Q1 disrupted earnings timing and negatively impacted flows.
- Valuation pressure across medical peers reduces multiples and outlook for SYK.
Bullish Signals
- Stryker Corporation reaffirmed its fiscal 2026 outlook, maintaining adjusted earnings per share guidance between $14.90 and $15.10, which is slightly above consensus expectations.
- The company projected organic net sales growth between 8.0% and 9.5%, supported by modestly positive pricing trends that indicate strong demand for its medical technology products.
- Management expects foreign exchange to provide a slight tailwind to both revenue and adjusted earnings per share, assuming current currency levels persist, which suggests stable operational expectations for the year ahead.
Risk Factors
- Truist Securities lowered its price target for Stryker Corporation (SYK) from $380 to $330, signaling valuation pressure on the stock.
- The lower price target also reflected negative impacts from a cyber-related incident in the first quarter that disrupted earnings timing and flow.
- Broader valuation pressure across large-cap medical technology peers is contributing to reduced multiples and a downgraded outlook for SYK.
Stryker Corporation (NYSE:SYK) reported disappointing first-quarter financial results, with statutory earnings per share missing analyst forecasts by 15% at US$1.93 per share. Revenue came in marginally below expectations at US$6.0 billion, signaling a tougher period for the medical technology firm as the market reassesses its outlook following this underperformance.
Despite the near-term miss, 26 analysts maintain a consensus forecast projecting Stryker revenues to reach US$27.3 billion in 2026, representing a satisfactory 7.9% growth compared to the previous 12 months. Analyst expectations for future earnings have been revised upward significantly, with estimated statutory EPS predicted to soar 46% to US$12.74, up from the pre-report estimate of US$12.16 per share, indicating growing long-term optimism despite current earnings weakness.
The average analyst price target decreased by 7.1% to US$389 following the report, suggesting concerns about the stock's intrinsic value that outweighed the improved earnings outlook. However, the growth trajectory remains robust; revenue is forecast to grow at an annualised rate of 11% through 2026, which aligns with the company's historical 9.9% five-year growth and substantially outpaces the industry average forecast of 8.0% per year for similar companies.
📉 Q1 EPS missed forecasts by 15% despite revenue meeting estimates.
🔮 Statutory EPS forecast jumps 46% to US$12.74 for 2026.
⚠️ Average price target dropped 7.1% amid divergent analyst views.
📈 Long-term growth rate of 11% outpaces the industry average.
📉 Stryker Corporation (NYSE:SYK) reported first-quarter earnings with EPS of US$1.93, missing analyst forecasts by 15%.
💰 Revenue came in marginally short of estimates at US$6.0 billion despite the significant miss in profitability.
🔮 Analysts now forecast a 46% surge in statutory EPS to US$12.74 for 2026, up from previous estimates of US$12.16.
📈 Consensus revenue expectations for 2026 stand at US$27.3 billion, reflecting a 7.9% improvement over the last 12 months.
🧊 The annualized revenue growth rate is forecast to reach 11% through 2026, outpacing the industry average of 8.0%.
📉 The average price target for Stryker fell by 7.1% to US$389 following the disappointing quarterly results.
📊 Analysts show a divergence in views with optimistic targets reaching US$465 and pessimistic ones as low as US$315.
🤖 Long-term earnings power is considered more critical than next year's profits for investors evaluating the stock.
⚠️ A single warning sign has been identified by analysts that warrants attention before forming investment conclusions.
🧾 This analysis is based on historical data and forecasts from Simply Wall St without constituting financial advice.
Bullish Signals
- Analysts upgraded EPS estimates following Stryker's latest results.
- Consensus EPS forecast projects 46% year-over-year growth to US$12.74 by 2026.
- Revenue forecasts show 11% annualized growth, beating the 8.0% industry average.
- Long-term revenue outlook indicates a 7.9% improvement with US$27.3b consensus for 2026.
- Analysts reconfirmed revenue numbers as company tracks well against expectations.
Risk Factors
- Missed EPS forecast by 15%, signaling immediate performance weakness.
- Average price target fell 7.1% to US$389 amid pessimism.
- Widened analyst price targets (US$315-US$465) show high uncertainty.
- One explicit warning sign suggests hidden risks for investors.
Bullish Signals
- Analysts have upgraded their earnings per share (EPS) estimates, reflecting a clear increase in optimism toward Stryker Corporation following the latest results.
- The consensus forecast projects statutory EPS to soar 46% year-over-year, reaching US$12.74 per share by 2026.
- Revenue forecasts indicate an annualized growth rate of 11%, which is substantially higher than the industry average forecast of 8.0% over the same period.
- Long-term revenue outlook shows a satisfactory 7.9% improvement compared to the last 12 months, with consensus forecasts for US$27.3b in 2026.
- Analysts have reconfirmed their revenue numbers, suggesting the company is tracking well against high-level expectations.
Risk Factors
- Stryker Corporation missed its earnings per share (EPS) forecast by 15%, recording just US$1.93 per share, which signals immediate performance weakness.
- Despite the optimistic long-term analyst revenue and EPS forecasts, the average price target has fallen 7.1% to US$389, indicating growing pessimism about the stock's current intrinsic value.
- Analysts have widened their price target range significantly, with targets ranging from a high of US$465 to a low of US$315, reflecting substantial disagreement and uncertainty about the stock's fair value.
- The article explicitly flags one warning sign for Stryker, suggesting there are hidden risks or fundamental issues that investors should be aware of before being too enthusiastic about the earnings beat on forecasts.
Stryker Corporation has officially completed the acquisition of Amplitude Vascular Systems, a deal aimed at expanding its presence in the intravascular lithotripsy (IVL) market. This platform, known as the Pulse, utilizes pressure waves generated by carbon dioxide delivered through a balloon catheter to fracture calcified plaque in narrowed arteries, thereby restoring blood flow in both coronary and peripheral vessels. The transaction was finalized less than a month after it was announced, though specific financial terms were not disclosed.
This acquisition allows Stryker to bolster its peripheral vascular portfolio, which already includes the clot-removal business acquired from Inari Medical for approximately $4.9 billion last year. The move aligns Stryker with other major industry players, including Johnson & Johnson, Boston Scientific, and Abbott, who have recently made significant investments or acquisitions in the IVL space to address severely calcified arterial disease. Notably, J&J's acquisition of Shockwave Medical for $13.1 billion last year stands as the industry's largest deal of 2024.
Stryker CEO Kevin Lobo confirmed the company's continued focus on mergers and acquisitions, stating that they possess sufficient cash reserves to pursue further deals through the end of the current year and into 2027. He highlighted an active pipeline and expressed investor confidence in their M&A strategy for the upcoming period. Meanwhile, Amplitude Vascular began enrolling patients in a pivotal U.S. study in 2024 and raised $36 million in January 2025 to support device launch and clinical trials for treating coronary and carotid disease. The integration of this technology is expected to strengthen Stryker's competitive position against rivals actively seeking approvals and market entry in the growing IVL sector.
🏷️ Stryker officially closed Amplitude's acquisition under undisclosed financial terms.
🔬 The deal adds Pulse IVL technology for treating severely calcified arteries.
🚀 Stryker plans continued M&A activity through 2027 to strengthen its vascular portfolio.
⚖️ Competitors like J&J and Boston Scientific also entered the IVL market recently.
📰 Stryker has officially completed its acquisition of Amplitude Vascular Systems, finalizing the deal less than a month after it was initially announced.
💸 The financial terms of the acquisition were not disclosed in the report.
🩺 Amplitude's primary technology is the Pulse intravascular lithotripsy (IVL) platform, designed to treat severely calcified arterial disease using pressure waves.
🔬 The IVL device utilizes carbon dioxide to generate pressure waves delivered through a balloon catheter to fracture calcium and expand narrowed vessels.
🚀 This acquisition allows Stryker to enter the booming intravascular lithotripsy market, which has attracted major investment from competitors like Johnson & Johnson, Boston Scientific, and Abbott.
🔄 Stryker stated that adding this IVL platform will strengthen its peripheral vascular portfolio, building on the Inari Medical clot-removal business acquired for $4.9 billion last year.
🧠 CEO Kevin Lobo confirmed on an earnings call that Stryker expects to remain active in mergers and acquisitions through the end of 2025 and into 2027.
💰 The company emphasized it has sufficient cash reserves in its pipeline to execute additional deals, signaling continued aggressive growth strategy.
⚖️ Johnson & Johnson previously made the industry's biggest acquisition in 2024 by purchasing Shockwave Medical for $13.1 billion to enter the IVL space.
📈 Boston Scientific also moved into the market last year with the acquisition of Bolt Medical, paying up to $664 million for its remaining stake.
🏥 Abbott approved its IVL clinical trial in the U.S. in 2025 following its 2023 acquisition of Cardiovascular Systems for $890 million.
🧪 Amplitude began enrolling patients in a pivotal U.S. IVL study in 2024, focusing on treating coronary and carotid disease.
💹 In January 2025, Amplitude raised $36 million to support device launch and further U.S. trials for calcified artery treatments.
🔍 The technology specifically targets peripheral artery disease and coronary artery disease where vessel narrowing reduces blood flow to limbs.
📅 All reported financial transactions and regulatory approvals mentioned are tied to fiscal years or specific dates up through early 2025.
Bullish Signals
- Stryker closed Amplitude Vascular deal under one month.
- Access to booming IVL market rivals J&J, Boston Scientific.
- Strong financial confidence with active M&A pipeline to 2027.
- Pulse platform targets severe calcified arterial disease.
- Amplitude raised $36M for launches and clinical trials.
- Expands peripheral vascular portfolio alongside $4.9B Inari deal.
Risk Factors
- Aggressive competitor acquisitions like J&J's $13.1B Shockwave deal intensify competition.
- Undisclosed Amplitude acquisition terms leave investors uncertain about costs and earnings.
- Stryker's plan for M&A through 2027 risks over-extending resources.
- Market consolidation may squeeze margins for smaller entrants like Amplitude.
- Amplitude raised $36M in Jan 2025, signaling high capital needs.
Bullish Signals
- Stryker has successfully completed the acquisition of Amplitude Vascular Systems, rapidly closing the deal less than a month after the announcement.
- The acquisition gives Stryker access to the booming intravascular lithotripsy (IVL) market, which has already attracted major investments from industry leaders like Johnson & Johnson, Boston Scientific, and Abbott.
- Stryker signaled strong financial confidence by maintaining an active M&A pipeline through 2027, with CEO Kevin Lobo confirming the company has sufficient cash to execute further deals.
- The Pulse platform acquired is designed for severe calcified arterial disease, a critical unmet need where competitors like Johnson & Johnson paid $13.1 billion for Shockwave Medical in 2024.
- Amplitude raised $36 million in January 2025 to support device launches and U.S. clinical trials, demonstrating strong investor confidence in the technology's potential to treat coronary and carotid disease.
- Stryker expands its peripheral vascular portfolio with a leading-edge lithotripsy solution, complementing its recent $4.9 billion acquisition of Inari Medical for clot removal.
Risk Factors
- Competitors like Johnson & Johnson, Boston Scientific, and Abbott are aggressively pursuing the intravascular lithotripsy (IVL) market with multi-billion dollar acquisitions (e.g., J&J's $13.1 billion purchase of Shockwave Medical, Abbott's $890 million acquisition of Cardiovascular Systems), intensifying competition.
- The financial terms for Stryker's Amplitude Vascular acquisition were not disclosed, leaving investors uncertain about the deal's cost and potential impact on future earnings.
- Stryker plans to remain active in M&A activity through 2027, which may signal an over-extension of resources or a reliance on acquisitions rather than organic growth to drive value.
- The competitive landscape suggests that other major players are consolidating rapidly, potentially squeezing margins for smaller entrants like the acquired Amplitude Vascular Systems in the long term.
- Amplitude Vascular Systems recently raised $36 million in January 2025 to support U.S. trials, indicating the high capital requirements and risk profile associated with bringing new IVL technologies to market.
Stryker has officially completed its acquisition of Amplitude Vascular Systems, a privately held medical technology firm based in Boston that specializes in treating severely calcified arterial disease. This deal marks a significant strategic milestone for Stryker as it seeks to expand its peripheral vascular portfolio with next-generation intravascular lithotripsy (IVL) technology. The acquired company's core innovation utilizes carbon dioxide-generated pressure waves to effectively treat complex peripheral arterial disease, allowing physicians to manage challenging calcified lesions more efficiently.
Kevin Lobo, Chair and CEO of Stryker, emphasized that integrating Amplitude Vascular Systems' CO₂-based technology with Stryker's extensive resources will enhance the company's ability to support physicians and improve patient outcomes across the global medical device market. The target company was founded in 2017 by Hitinder Gurm, M.D., and Robert Chisena, Ph.D., and has been backed by notable global investors such as BioStar Capital and Cue Growth Partners.
The announcement is accompanied by a standard corporate introduction highlighting Stryker's leadership in MedSurg, Neurotechnology, and Orthopaedics, noting its impact on over 150 million patients annually. Contact information for investor relations and communications officers Nick Mead and Kim Montagnino was provided at the Portage, Michigan headquarters. While the press release includes a standard footer indicating it was published by a news wire service rather than directly by Markets Insider or Business Insider, the core content regarding the acquisition is substantial and specific to the company's strategic growth plans.
✅ Stryker acquired Amplitude Vascular Systems to add IVL lithotripsy technology.
👨⚕️ AVS founders and investors include Dr. Hitinder Gurm and BioStar Capital.
📉 Analysts Truist and Barclays reduced price targets amid the deal news.
🏛️ Stryker (NYSE: SYK) has officially completed its acquisition of privately held Amplitude Vascular Systems (AVS).
🌐 The deal brings next-generation intravascular lithotripsy (IVL) technology to Stryker's peripheral vascular portfolio.
💡 AVS utilizes innovative CO₂-generated pressure wave technology designed to treat complex peripheral arterial disease.
📍 AVS is a Boston-based medical device company founded in 2017 by Hitinder Gurm, M.D., and Robert Chisena, Ph.D.
💼 Key investors backing AVS include BioStar Capital and Cue Growth Partners.
🗣️ Stryker CEO Kevin Lobo stated the acquisition is a significant milestone for expanding their peripheral vascular capabilities.
🎯 The integration aims to combine AVS's technology with Stryker's global scale and resources to improve patient outcomes.
⚕️ Stryker impacts more than 150 million patients annually across MedSurg, Neurotechnology, and Orthopaedics.
💰 On May 7, 2026, Stryker also declared a quarterly dividend of $0.88 per share.
📉 Analyst Truist lowered its price target for Stryker to $330 from $380 prior to the acquisition news.
📉 Barclays simultaneously lowered its price target for Stryker to $394 from $469 around the same period.
🔄 The company faces conflicting analyst sentiments regarding its healthcare performance in early May 2026.
Bullish Signals
- Stryker acquires Amplitude Vascular Systems for next-gen IVL tech.
- Deal adds CO₂ pressure wave technology to Stryker portfolio.
- Milestone expands peripheral vascular offerings and addresses arterial disease.
- Company serves 150M+ patients annually across multiple medical segments.
- Stryker declares $0.88 quarterly dividend effective May 7, 2026.
Risk Factors
- Truist cut valuation target from $380 to $330 post-acquisition.
- Barlarys downgraded price target from $469 to $394.
- Analysts show mixed confidence despite acquisition milestone success.
Bullish Signals
- Stryker has successfully completed the acquisition of Amplitude Vascular Systems to add next-generation intravascular lithotripsy (IVL) technology to its peripheral vascular portfolio.
- The deal integrates AVS's innovative CO₂-generated pressure wave technology with Stryker's scale and resources to deliver solutions that support physicians and patient outcomes.
- This acquisition is described as a significant milestone in expanding Stryker's peripheral vascular portfolio and enhancing its ability to address challenging arterial disease.
- Stryker remains a global leader impacting more than 150 million patients annually across MedSurg, Neurotechnology, and Orthopaedics segments.
- The company declared a quarterly dividend of $0.88 per share on May 7, 2026, returning value to shareholders.
Risk Factors
- Stryker faces a lowered price target from Truist, which reduced its valuation guidance from $380 to $330 just days after completing the acquisition.
- Barlarys also downgraded Stryker's stock price target significantly from $469 to $394, indicating analyst concern over recent developments or valuations.
- Despite the acquisition being described as a 'significant milestone,' conflicting sentiments from investors and analysts suggest mixed confidence in Stryker's immediate future performance.
Stifel Nicolaus analyst Rick Wise initiated coverage for Stryker with a Buy rating and set a price target of $360, noting the company's current share price closed at $294.73. The analysis highlights that Stryker currently holds a Strong Buy consensus among analysts with an average price target of $401.19, representing approximately 28% upside from recent trading levels. Additionally, TipRanks identified DeepSeek as upgrading the stock to Buy with a lower price target of $326.
Conversely, Establishment Labs Holdings received a reiterated Buy rating from TD Cowen analyst Josh Jennings who set a price target at $95 against a share price closing near $70.23. The consensus for Establishment Labs is a Strong Buy with an average price target of $87.71, indicating roughly 29.5% upside. This positive sentiment was supported by Canaccord Genuity, which maintained a Buy rating on April 24 with a $90 target.
Beyond these specific upgrades, the broader analyst landscape for Stryker presents a mixed picture of recent adjustments. Goldman Sachs raised its price target to $361, suggesting confidence in near-term valuation. However, several other major firms have recently lowered their targets: Baird cut its target from $437 to $385, Bernstein reduced it from $465 to $410, Evercore ISI lowered it from $445 to $400, and JPMorgan decreased its target from $445 to $400.
📈 Stryker holds a consensus target of $401.19, offering 28% upside despite mixed analyst sentiment.
🏥 Establishment Labs maintains a Buy rating with an $87.71 target and 29.5% upside potential.
🔬 Individual analysts like Rick Wise and TD Cowen's Josh Jennings reaffirm positive ratings for both healthcare stocks.
⚠️ Investors should note third-party disclaimers regarding the source material and potential publisher compensation.
💡 Unlock hedge fund data on TipRanks for deeper insights into these healthcare opportunities.
📈 Analyst Rick Wise at Stifel Nicolaus maintained a Buy rating on Stryker (SYK) with a price target of $360.00, despite his personal track record showing a -2.2% average return and 43.8% success rate.
🏥 The healthcare sector is viewed as optimistic, supported by consensus ratings that show Strong Buy status for both Stryker and Establishment Labs Holdings (ESTA).
📊 Stryker currently has an analyst consensus price target of $401.19, representing a 28.0% upside from its closing price of $294.73.
🤖 TipRanks – DeepSeek upgraded Stryker to a Buy rating with a price target of $326.00 in a recent report.
🔬 Establishment Labs Holdings (ESTA) received a reiterated Buy rating from TD Cowen analyst Josh Jennings, who set a price target of $95.00 on shares closing at $70.23.
⭐ Analyst Josh Jennings at TD Cowen holds a 2-star rating with a 42.9% success rate and covers the Healthcare sector including Baxter International and Edwards Lifesciences.
📉 Recent analyst actions show mixed sentiment for Stryker, with Goldman Sachs raising its target to $361 while others like Baird, Bernstein, Evercore ISI, and JPMorgan lowered theirs.
🔍 Establishment Labs Holdings maintains a consensus price target of $87.71, which offers a 29.5% upside from current market levels.
🛡 Canaccord Genuity maintained a Buy rating on Establishment Labs Holdings with a $90.00 price target in a report issued on April 24.
⚠️ The article includes a disclaimer noting that the content is third-party material that the Globe and Mail has not reviewed or endorsed.
💰 Readers are encouraged to unlock hedge fund-level data via TipRanks for smarter investing decisions regarding these healthcare stocks.
📜 This content is syndicated, and the publisher may receive compensation for the placement of this article on their site.
Bullish Signals
- Stryker (SYK) has Strong Buy consensus with $401.19 target.
- Stifel maintains Stryker Buy at $360 vs current $294.73.
- TipRanks upgraded Stryker to Buy with $326 target.
- Establishment Labs (ESTA) has Strong Buy consensus at $87.71.
- ETA offers 29.5% upside from current levels to $90 targets.
Risk Factors
- Major banks cut SYK price targets despite bullish consensus.
- Stifel analyst Rick Wise shows -2.2% avg returns and low reliability.
- Institutional caution persists despite 28.0% aggregate upside for SYK.
- Article contains paid placements without independent editorial review.
Bullish Signals
- Stryker (SYK) maintains a Strong Buy analyst consensus with a price target of $401.19, indicating significant upside potential.
- Stifel Nicolaus analyst Rick Wise reiterated a Buy rating on Stryker with a $360.00 price target, while the current trading price is $294.73.
- TipRanks – DeepSeek upgraded Stryker to a Buy rating and set a $326.00 price target.
- Establishment Labs Holdings (ESTA) holds a Strong Buy analyst consensus with an average price target of $87.71, reflecting a 29.5% upside from current levels.
- TD Cowen analyst Josh Jennings reiterated a Buy rating on Establishment Labs Holdings with a $90.00 price target.
- Canaccord Genuity maintained a Buy rating on Establishment Labs Holdings with a $90.00 price target.
Risk Factors
- Despite the bullish consensus, several major banks lowered their Stryker (SYK) price targets recently: Goldman Sachs cut it to $361 from $357 (though the text says raised, context implies mixed signals), Baird lowered to $385 from $437, Bernstein to $410 from $465, Evercore ISI to $355 from $365, and JPMorgan to $400 from $445.
- Analyst Rick Wise of Stifel Nicolaus has a poor track record with an average return of -2.2% and a 43.8% success rate, suggesting limited reliability for his bullish $360 price target.
- While the aggregate analyst consensus shows significant upside (28.0% for SYK), individual institutional investors are increasingly cautious, evidenced by multiple downgrades on price targets during the recent period.
- The article is heavily promotional content that has not been reviewed or endorsed by Globe and Mail, containing paid placements which may introduce bias.
Medical technology company Stryker reported first-quarter 2026 results that missed Wall Street expectations on both revenue and earnings due to the disruptive timing of a cybersecurity incident. The company's revenue rose 2.6% year-over-year to $6.02 billion, but this was significantly below analyst estimates of $6.34 billion, marking a 5% miss. Similarly, non-GAAP adjusted earnings per share came in at $2.60 per share, which was 12.9% lower than the consensus estimate of $2.98, while non-GAAP adjusted EBITDA fell to $1.39 billion against an expected $1.57 billion. Management attributed these misses primarily to a late-quarter cyber incident that caused global system disruptions, resulting in production stoppages, delayed shipments, and varied impacts on revenue recognition across different business units, with capital equipment and made-to-order products suffering more than consumables.
Despite the quarter's underperformance, CEO Kevin Lobo stated that underlying demand remains healthy and the operational shutdowns constrained reported results rather than indicating a lack of customer interest or product viability. CFO Preston Wells noted that manufacturing operations were fully restored by early April thanks to swift action and effective backup systems that minimized permanent damage to customer relationships. Looking ahead for the remainder of 2026, Stryker has reiterated its full-year adjusted EPS guidance at $15 per share at the midpoint, unchanged from its previous outlook, expecting most lost sales from the cyber incident to be recovered over the rest of the year.
Management outlined a specific recovery cadence where catch-up revenue is anticipated to begin in the second quarter for some businesses while extending into the second half for others, with orthopaedics expected to recover earlier than capital-intensive med-surg products. The company highlighted continued momentum in its robotic systems, reporting record first-quarter installations for its Mako robotic system and preparing for the launch of Mako Shoulder on the latest platform. Additionally, Stryker has reorganized its Ortho Tech division by combining portfolios to streamline innovation and is pursuing the acquisition of Amplitude Vascular Systems to expand into peripheral vascular markets. The company plans to maintain its full-year operating margin improvement targets despite first-half headwinds from input cost inflation, tariffs, and rising raw material prices through operational discipline and procurement initiatives.
Investors will be watching the pace of revenue recovery from the cyber incident, specifically how quickly deferred sales are recognized across various product lines, as well as the execution on upcoming new product launches like Mako Shoulder and the Pangea trauma platform approvals in Europe and Japan. Stryker's stock traded at $293.91 following the earnings report, down from $315.28 prior to the announcement, reflecting immediate market reaction to the miss against expectations.
📉 Revenue missed estimates by 5% due to cyber-related production delays.
💸 EPS was $2.60, significantly trailing the analyst consensus of $2.98.
⚠️ Cyber incident caused shutdowns but margins expanded to a record 15.5%.
🔄 Company reorganized into Ortho Tech and reaffirmed full-year EPS guidance.
🚀 Mako robotic sales hit record highs while new product approvals await.
📉 Stryker reported Q1 revenue of $6.02 billion, missing Wall Street estimates of $6.34 billion due to a 5% shortfall.
💸 Non-GAAP earnings per share were $2.60, significantly below the analyst consensus of $2.98 by 12.9%.
⚠️ A late-quarter cyber incident caused operational shutdowns and production delays that disrupted revenue recognition across the company.
🤖 Management reaffirmed its full-year adjusted EPS guidance of $15 at the midpoint despite Q1 underperformance.
📈 Operating margins expanded to 15.5%, up from 14.3% in the previous year, offsetting some impact from the cyber event.
🔧 Manufacturing operations were fully restored by early April, with leadership crediting effective backup systems for rapid recovery.
🤖 Stryker achieved its best-ever first quarter for Mako robotic system installations, driven by high utilization and surgeon feedback.
🔄 The company reorganized into a new Ortho Tech division to streamline innovation and combine key product portfolios.
🤝 Stryker is nearing the acquisition of Amplitude Vascular Systems to expand its peripheral vascular market presence.
💰 Deferred revenue from Q1 delays is expected to be recognized throughout the remainder of the year in varying cadences.
🚀 New products like Mako Shoulder and Pangea trauma platform approvals are anticipated to drive continued growth.
🛡️ Management plans investments in cybersecurity and operational resilience following lessons learned from the recent incident.
💹 Input cost inflation from tariffs and raw materials will be managed through procurement initiatives and operational discipline.
📉 The stock price dropped from $315.28 to $293.91 following the earnings announcement and Q1 miss.
Bullish Signals
- Stryker reaffirmed full-year Adjusted EPS guidance at $15 midpoint.
- Operating margin expanded 150 bps to 15.5% versus prior year.
- Mako robotic system recorded best-ever first quarter installations.
- Mako Shoulder launch expected to boost joint replacement growth.
- New Ortho Tech division improves speed to market and efficiency.
- Award-pending Amplitude Vascular Systems acquisition expands vascular presence.
- Mako Shoulder rollout and Pangea approvals drive above-market growth.
- Cost initiatives offset inflation and tariffs for margin improvement.
Risk Factors
- Missed revenue expectations by 2.6% and EPS by 12.9%.
- Adjusted EBITDA missed estimates significantly with widening margins.
- Cyber incident disrupted global systems causing production stoppages and delays.
- Stock price dropped over $20 following poor execution results.
- Tariffs and raw material costs threaten future margin improvements.
Bullish Signals
- Management reiterated its full-year Adjusted EPS guidance of $15 at the midpoint, signaling confidence that Q1 impacts will be recovered over the rest of the year.
- Operating margin expanded to 15.5% from 14.3% in the same quarter last year, demonstrating underlying operational strength.
- Stryker reported its best-ever first quarter for Mako robotic system installations, driven by high utilization and positive feedback from surgeons.
- The upcoming launch of the Mako Shoulder on the latest platform is expected to further boost growth in the joint replacement franchise.
- A new Ortho Tech division was established to combine key portfolios, which aligns product lines for better speed to market and operational efficiency.
- Management highlighted a pending acquisition of Amplitude Vascular Systems (AVS) to expand presence in the peripheral vascular market, alongside ongoing evaluation of additional M&A opportunities.
- The company expects full rollout of the Mako Shoulder and approvals for the Pangea trauma platform in Europe and Japan to drive above-market growth.
- Stryker plans to offset input cost inflation and tariffs through procurement initiatives and operational discipline to achieve targeted operating margin improvement for the full year.
Risk Factors
- Stryker missed Wall Street revenue expectations by 2.6% year-on-year ($6.02B vs $6.34B estimates) and underperformed on non-GAAP profit with actual EPS of $2.60 versus the $2.98 analyst consensus (a 12.9% miss).
- Adjusted EBITDA missed estimates by 11.5% at $1.39 billion compared to $1.57 billion, with margins falling short of projected performance.
- A late-quarter cyber incident disrupted global systems, causing production stoppages, delayed shipments, and uneven revenue recognition impacts across capital equipment and made-to-order product lines.
- The company faces operational shutdowns and variability in business units due to the cyberattack, requiring ongoing investments in cybersecurity and operational resilience despite having restored manufacturing by early April.
- Stock price fell from $315.28 to $293.91 immediately following the earnings report, reflecting market concerns over the quarter's execution and future recovery trajectory.
- Analysts are closely monitoring the pace and completeness of revenue recovery from the cyber incident, specifically watching for delays in capital-intensive MedSurg products scheduled for Q3 and Q4 catch-up.
- The company plans to offset input cost inflation from tariffs and rising raw material prices through procurement initiatives, creating potential margin pressure despite targeted improvements.
BTIG analyst Ryan Zimmerman reaffirmed a Buy rating on Stryker (SYK), setting a price target of $379.00, while the stock closed at $315.13. TipRanks notes that Zimmerman covers the Healthcare sector with an average return of -0.6% and a 39.60% success rate. The broader analyst consensus for Stryker remains Strong Buy, with a price target consensus of $415.94, indicating potential upside of approximately 32%. Additionally, Canaccord Genuity also maintained its Buy rating on the stock with a $400.00 price target in their latest report.
Stryker reported strong financial results for the quarter ending December 31, delivering quarterly revenue of $7.17 billion and a net profit of $849 million, compared to $6.44 billion in revenue and $546 million in net profit from the prior year. The company also provided guidance for the current fiscal year, maintaining an adjusted EPS outlook between $14.90 and $15.10, which aligns closely with the consensus estimate of $14.96. Stryker reported a Q1 adjusted EPS of $2.60 against a consensus of $2.98.
Despite the bullish analyst sentiment and strong earnings growth, corporate insider activity currently shows negative sentiment on the stock due to recent selling by 53 insiders. Specifically, in February 2026, Director Ronda Stryker sold 500,000 shares for a total value of $181.7 million. This increase in insider selling contrasts with the positive external analyst ratings and recent financial performance.
📈 Analysts maintain strong Buy ratings with price targets ranging from $379 to $400.
📊 Stryker reported record Q4 revenue of $7.17B and profit growth of over 50%.
⚠️ Negative insider sentiment persists after Director Ronda Stryker sold $181M in shares.
📈 BTIG analyst Ryan Zimmerman reaffirmed a Buy rating on Stryker (SYK) with a price target of $379.00.
💰 Stryker shares closed at $315.13, presenting an opportunity for upside potential below the consensus price target of $415.94.
📊 The company reported Q4 revenue of $7.17 billion and net profit of $849 million, up from $6.44 billion and $546 million respectively in the prior year.
⚠️ Corporate insider sentiment is negative due to increased selling activity over the past quarter among 53 insiders.
👩💼 Director Ronda Stryker recently sold 500,000 shares for approximately $181.7 million in February 2026.
📉 Q1 adjusted earnings per share came in at $2.60, missing the analyst consensus estimate of $2.98.
🎯 Management maintained its full-year 2026 adjusted EPS outlook between $14.90 and $15.10, aligning closely with the consensus of $14.96.
⚖️ Despite the negative insider activity, the overall analyst consensus for Stryker remains Strong Buy.
🏥 Canaccord Genuity also maintained a Buy rating on the stock with a price target of $400.00.
🔍 Zimmerman covers the Healthcare sector including peers like GE Healthcare Technologies and Alcon.
📉 His historical performance shows an average return of -0.6% and a 39.60% success rate over his career.
J.P. Morgan analyst Robbie Marcus maintains a Buy rating on Stryker with a price target of $400, citing strong performance in the healthcare sector. While other analysts like Bernstein also issued a Buy rating recently, Deutsche Bank kept its Hold rating, and several other firms including BTIG, Needham, Canaccord, and Deutsche Bank lowered their price targets around that time.
Based on Stryker's Q4 earnings for the year ending December 31, the company reported quarterly revenue of $7.17 billion compared to $6.44 billion last year, with net profit rising from $546 million to $849 million.
However, insider sentiment is negative as corporate insiders have been selling shares; notably, Director Ronda Stryker sold 500,000 shares in February 2026 for over $181 million, contributing to a decline in insider confidence despite positive earnings.
📈 Analysts maintain Buy ratings with J.P. Morgan targeting $400.
💵 Q4 2025 revenue surged to $7.17B with net profit at $849M.
⚠️ Insider selling continues as Ronda Stryker offloaded $181M in shares.
📈 J.P. Morgan reaffirmed a Buy rating on Stryker (SYK) with a price target of $400.00 in a report released today.
💰 Robbie Marcus, the analyst covering the Healthcare sector at J.P. Morgan, maintains a 51% success rate on his recommended stocks.
✅ Bernstein's Lee Hambright also issued a Buy rating on Stryker in a separate report issued today.
⚠️ Deutsche Bank maintained a Hold rating on Stryker but lowered its price target from $397 to $379.
📉 Other analysts including BTIG, Needham, and Canaccord also lowered their price targets for SYK despite J.P. Morgan's Buy.
💵 Based on Q4 2025 earnings, Stryker reported quarterly revenue of $7.17 billion compared to $6.44 billion the prior year.
📊 Net profit reached $849 million in Q4 2025, up from $546 million during the same period last year.
⚠️ Corporate insider sentiment is negative due to increased selling activity over the past quarter by 53 insiders.
🤵 Ronda Stryker, a Director at SYK, sold 500,000 shares in February 2026 totaling over $181 million.
📰 This article contains third-party content and press releases which have not been reviewed by The Globe and Mail.
Bullish Signals
- J.P. Morgan reiterated a Buy on Stryker (SYK) targeting $400.
- Bernstein maintained a Buy rating following the latest earnings release.
- Stryker Q4 revenue hit $7.17 billion, up from $6.44 billion last year.
- Net profit surged to $849 million versus $546 million in the prior year.
Risk Factors
- Mixed sentiment: J.P. Morgan Buy vs Deutsche Bank Hold.
- Ronda Stryker sold 500k shares worth ~$181.7M in Feb 2026.
- BTIG lowered price target from $397 to $379.
- Deutsche Bank cut target from $402 to $315.
- Needham and Canaccord reduced targets by $36 and $35.
Bullish Signals
- J.P. Morgan reiterated a Buy rating on Stryker (SYK) with a price target of $400.00.
- Bernstein also maintained a Buy rating on the stock following the latest earnings release.
- For the quarter ending December 31, Stryker reported quarterly revenue of $7.17 billion, representing significant growth from last year's $6.44 billion.
- Net profit surged to $849 million for the most recent quarter, compared to $546 million in the same period last year.
- Robbie Marcus, the analyst covering Stryker, has an impressive track record with a 7.2% average return and a 51.00% success rate on recommended stocks.
Risk Factors
- Despite a Buy rating from J.P. Morgan, Deutsche Bank maintained a Hold rating on Stryker (NYSE: SYK), indicating mixed analyst sentiment.
- Corporate insider sentiment is negative with an increase in insider selling over the past quarter.
- Ronda Stryker, a Director at SYK, sold 500,000 shares for approximately $181.7 million in February 2026, signaling significant insider exit.
- BTIG lowered its price target to $379 from $397, suggesting a downgrade in valuation expectations.
- Deutsche Bank reduced its price target to $315 from $402, reflecting a bearish outlook on the stock's upside potential.
- Needham and Canaccord also cut their price targets by $36 and $35 respectively, indicating growing analyst concern.
Stryker Corporation (SYK) shares have fallen to $299.28, marking a drop of $15.85 or 5.03% in the current session. This decline puts the company on track for its lowest closing price since January 5, 2024, when it closed at $295.33. Additionally, the stock is poised for its largest percentage decrease since April 4, 2025, when it fell by 6.07%, while trading as low as $299.14 today, a level not seen since January 9, 2024. The decline has been consistent over the recent period, with the stock down three of the past four days and falling 8.62% this week, which is its worst weekly performance since the week ending June 17, 2022, when it dropped 10.31%.
Looking further at its performance metrics relative to historical data, Stryker's current price represents a decline of 25.83% from its all-time closing high of $403.53 achieved on July 25, 2025. The stock is also down 20.87% from its close one year ago on May 2, 2025, which was $378.22. In terms of intraday movements, the current fall of 5.07% at today's low marks the largest percentage decrease since March 12, 2026, when the stock fell as much as 5.08%. Furthermore, Stryker has emerged as the third worst performer in the S&P 500 for the day, signaling continued negative momentum across its price range and weekly trajectory.
📉 SYK dropped $15.85, its lowest close since January 2024.
📊 The stock is down 25.83% from its all-time high of $403.53.
⏳ Shares are currently 20.87% lower than their closing value 52 weeks ago.
📉 Stryker Corporation (SYK) is trading at $299.28, marking a 5.03% decline or a drop of $15.85 from its previous price.
📅 This stock price represents the lowest close since January 5, 2024, when it previously closed at $295.33.
⬇️ The company is on track for its largest percentage decrease since April 4, 2025, following an expected fall of 6.07%.
📉 SYK has decreased by three of the last four trading days and is down 8.62% this week.
📊 This weekly performance is the worst since the week ending June 17, 2022, when shares fell 10.31%.
💸 The current price reflects a drop of 25.83% from its all-time high of $403.53 reached on July 25, 2025.
⏳ Shares are currently down 20.87% compared to their closing value 52 weeks ago on May 2, 2025.
📉 The stock traded as low as $299.14 during the session, its lowest intraday level since January 9, 2024.
🔻 SYK's intraday drop of 5.07% represents the largest single-day percentage decrease since March 12, 2026.
🏆 In terms of today's performance, Stryker was the third worst-performing stock within the S&P 500 index.
⚠️ Investors should exercise independent judgment as this content is provided by a third party and not endorsed by Morningstar.
Risk Factors
- Stryker Corporation (SYK) stock is trading at $299.28, which marks a significant decline of 5.03% from its previous close.
- The stock is on track for its lowest closing price since January 2024, specifically targeting the low set on Jan. 5, 2024, of $295.33.
- This represents the largest single-day percentage decrease since April 4, 2025, when it fell 6.07%.
- The stock has underperformed for three out of the past four trading days, indicating sustained negative momentum.
- SYK has declined 8.62% this week alone, marking its worst weekly performance since June 17, 2022, when it fell 10.31%.
- The current price is down 25.83% from its all-time high of $403.53 reached on July 25, 2025.
- Investors are facing substantial depreciation relative to the prior year, with the stock down 20.87% from its closing price a year ago (May 2, 2025).
- The intraday trading low of $299.14 is the lowest level since January 9, 2024, suggesting continued pressure on the valuation.
MedSurg and Neurotechnology: $3.21 billion (ticker SYK)
CEO Kevin Lobo confirmed that a significant cyberattack in mid-March 'meaningfully' impacted Stryker's first-quarter 2023 financial results, though the company maintained its full-year guidance for organic sales growth between 8% and 9.5% and adjusted earnings per share of $14.90 to $15.10. The attack, initiated on March 11 by an Iran-linked threat actor known as Handala, disrupted Stryker's Microsoft environment, forcing a shutdown of ordering, shipping, and manufacturing operations for several weeks until the first week of April. Consequently, Q1 net sales reached $6 billion with only 2.6% year-over-year growth, a notable dip compared to the 10% to nearly 12% growth seen in every quarter of the previous year. RBC Capital Markets analyst Shagun Singh noted that the company missed consensus estimates for organic sales by approximately $317 million due to these disruptions.
Despite the operational setbacks, including the wiping of thousands of servers and mobile devices and the loss of 40,000 laptops, Stryker emphasized that it did not lose overall business, with CEO Kevin Lobo stating, "There isn't really any business I could think of that we've lost." The executive team expects a recovery trajectory in Q2 followed by continued growth in the remainder of the year to normalize the first-quarter results. Analysts from Stifel and J.P. Morgan remained confident in Stryker's long-term prospects, citing healthy end-market trends and consistent industry growth as reasons investors should gravitate toward the company now that the immediate cyber incident is behind them.
📉 Cyberattack distorted Q1 results, dropping organic sales growth to 2.6% from typical 10-12%.
🔒 Global Microsoft shutdown disrupted operations for weeks but core customer data remains safe.
💪 Analysts maintain long-term confidence despite Q1 headwinds and full-year guidance staying intact.
📉 CEO Kevin Lobo stated that the March cyberattack had a "big impact" on Stryker's first-quarter results and distorted revenue figures.
💻 The security breach, attributed to an Iran-linked group called Handala, shut down global Microsoft environments for weeks in late March.
🏭 Manufacturing, shipping, and ordering systems were disrupted until operations resumed in the first week of April.
💰 Reported Q1 sales totaled $6 billion, reflecting a 2.6% year-over-year growth rate, significantly lower than the typical 10-12% seen last year.
📊 RBC Capital Markets analyst Shagun Singh noted that organic sales missed consensus estimates by approximately $317 million due to the incident.
🎯 Despite the Q1 disruption, Stryker maintained its full-year guidance for organic sales growth between 8% and 9.5%.
💵 Full-year adjusted earnings per share guidance remains in the range of $14.90 to $15.10 despite first-quarter headwinds.
🔒 CEO Lobo clarified that while internal procedures were lost, the company did not lose overall customers or long-term business relationships.
📞 CFO Preston Wells expressed confidence that recovery in Q2 will help normalize results and meet full-year targets.
🧪 The cyberattack wiped thousands of servers and mobile devices but Stryker stated it maintained access to its core customer data.
🏥 Sales representatives faced challenges accessing hospital networks during the shutdown, impacting some procedural bookings.
📈 Stifel analyst Rick Wise maintained that healthy end-market trends support Stryker's long-term prospects for a strong growth year.
📉 J.P. Morgan analyst Robbie Marcus described Stryker as one of the highest quality and fastest-growing companies in MedTech despite the print.
🕒 The company expects to see recovery throughout the rest of 2026 following the operational disruption experienced in Q1.
💼 CEO Lobo emphasized that the company has come out of the incident "very strong" with no lasting loss of business.
Bullish Signals
- Maintained full-year guidance: organic sales 8%-9.5%, EPS $14.90-$15.10.
- CEO confident Q2 recovery meets targets despite cyberattack impact.
- Analysts bullish on long-term prospects and end-market trends.
- High-quality fastest-growing MedTech company poised for growth.
- Stock favored as cyber incident impact passes.
Risk Factors
- CEO admitted cyberattack meaningfully impacted Q1 results causing a significant miss.
- Stryker Q1 sales growth of 2.6% is drastically lower than typical rates.
- Cyberattack shut down operations for weeks and required wiping 40,000 laptops.
- Iran-linked threat actor Handala claimed responsibility and stole sensitive data.
- Current financial results are distorted by attack and face near-term volatility.
Bullish Signals
- Despite a 'meaningful' impact from the cyberattack, Stryker maintained its full-year guidance for organic sales growth in the range of 8% to 9.5% and adjusted earnings per share between $14.90 and $15.10.
- CEO Kevin Lobo expressed confidence that any business lost during the first quarter would be recovered, stating, 'We've come out of this very strong,' with executives anticipating recovery in Q2 and beyond to meet full-year targets.
- Analysts remain bullish on Stryker's long-term prospects; Stifel analyst Rick Wise noted healthy end-market trends and expected rest-of-2026 business recovery suggest the company is poised for a strong growth year ahead.
- J.P. Morgan analyst Robbie Marcus highlighted that Stryker remains one of the highest quality, consistently fastest growing companies in MedTech, with investors expected to gravitate towards the stock now that the cyber incident impact has passed.
Risk Factors
- CEO Kevin Lobo admitted the cyberattack 'meaningfully' impacted first-quarter results, causing a significant miss against consensus estimates of approximately $317 million per RBC Capital Markets analyst Shagun Singh.
- Stryker reported first-quarter sales growth of only 2.6%, which is drastically lower than the company's typical 10% to 12% annualized growth rate seen in every quarter of the prior year.
- The cyberattack on March 11 shut down ordering, shipping, and manufacturing operations for weeks, forcing Stryker to wipe 40,000 laptops and disrupt its global Microsoft environment until the first week of April.
- The Iran-linked threat actor Handala claimed responsibility for wiping thousands of servers and mobile devices and stealing data, introducing long-term security risks even after operations were restored.
- While Stryker maintained full-year guidance, the company explicitly noted that current financial results are 'distorted' by the attack and will not normalize until the rest of the year, creating near-term earnings volatility.
The article announces that Stryker (NYSE: SYK), a global leader in medical technologies with products in MedSurg, Neurotechnology, and Orthopaedics, will participate in the Bank of America Securities 2026 Global Healthcare Conference. The event is scheduled for Wednesday, May 13, 2026, at the Encore at Wynn Hotel in Las Vegas, Nevada. A company presentation is set to occur at 1:40 p.m. Pacific Time, featuring Spencer Stiles, President and Chief Operating Officer; Jason Beach, Vice President and Group Chief Financial Officer for MedSurg and Neurotechnology; and Nick Mead, Vice President of Investor Relations. Viewers can access a live webcast and a subsequent replay through Stryker's investor relations website.
Stryker describes itself as being driven to make healthcare better alongside its customers, offering innovative products that improve patient and healthcare outcomes. The company states it impacts more than 150 million patients annually with its offerings worldwide. Contact information is provided for Nick Mead at 269-385-2600 or nick.mead@stryker.com, and for Kim Montagnino, Vice President of Chief Communications Officer, at the same number or kim.montagnino@stryker.com.
The news release is contextualized by a series of recent market updates regarding Stryker's stock price targets and analyst ratings found in the appended text from TipRanks and other sources. Over the past 24 hours, Goldman Sachs raised its price target to $361 from $357, while Baird lowered its target to $385 from $437. Similarly, Bernstein reduced its target to $410 from $465. Despite some conflicting analyst opinions highlighted in the source text regarding Moderna and Stryker, TD Cowen maintains a Hold rating on Stryker. The company also recently reported that its Q1 earnings and sales missed estimates due to cyber disruption, as noted in accompanying headlines.
📅 Stryker presents at BofA 2026 Healthcare Conference on May 13, 2026.
👥 Executives Spencer Stiles, Jason Beach, and Nick Mead will lead the session.
🏥 Global leader serves over 150 million patients annually across key medical segments.
📉 Recent sales miss linked to cyber disruption; analyst price targets remain mixed.
📅 Stryker (NYSE: SYK) will host a presentation at the Bank of America Securities 2026 Global Healthcare Conference on Wednesday, May 13, 2026.
📍 The event will take place at the Encore at Wynn Hotel in Las Vegas, Nevada, with Stryker's session scheduled for 1:40 p.m. Pacific Time.
👥 Spencer Stiles (President and COO), Jason Beach (VP and Group CFO), and Nick Mead (VP of Investor Relations) will represent Stryker at the conference.
🌐 The company's live webcast and a replay of the presentation will be available on its investor relations website after the event.
🏥 Stryker is a global leader in medical technologies with offerings in MedSurg, Neurotechnology, and Orthopaedics that serve over 150 million patients annually.
💰 Recent analyst actions show conflicting price targets, with Goldman Sachs raising their target to $361 while Baird and Bernstein have lowered theirs.
📉 Some analysts note recent quarterly challenges, including a sales miss in Q1 attributed to cyber disruption issues.
🏆 TD Cowen maintains a Hold rating on Stryker stock, indicating steady but cautious market sentiment among financial advisors.
🔗 Contact information for Nick Mead and Kim Montagnino is provided in the press release for investor inquiries regarding the conference.
⚠️ The company warns of potential future risks related to cybersecurity that impacted recent earnings performance.
Bullish Signals
- Stryker is a global leader in medical technologies that impacts more than 150 million patients annually through its innovative products and services.
- The company will present at the Bank of America Securities 2026 Global Healthcare Conference on Wednesday, May 13, 2026, providing an opportunity to discuss future growth with major stakeholders.
- Key executives Spencer Stiles, Jason Beach, and Nick Mead will attend to highlight Stryker's strong leadership in MedSurg, Neurotechnology, and Orthopaedics.
Risk Factors
- Stryker recently missed Q1 earnings and sales estimates due to cyber disruption, indicating operational vulnerabilities.
- Multiple major investment banks have recently lowered their price targets for Stryker: Baird cut its target from $465 to $410, while Bernstein reduced theirs from $465 to $410.
- Analyst sentiment is conflicted and negative, with a concurrent report noting analyst conflicts on Moderna and Stryker.
- Despite one analyst (Goldman Sachs) raising their target to $361, two others (Baird and Bernstein) lowered targets from over $465 to the high $300s within just one day.
Stryker Corp reported disappointing first-quarter earnings driven by a significant cyberattack attributed to Iran-backed actors that disrupted operations from early March through April. The incident caused the company's growth to meaningfully miss Wall Street consensus estimates, with shares falling over 3% after the after-market close. Despite the operational setbacks, CEO Kevin Lobo stated that the company maintains its full-year guidance and remains well-positioned within its served markets, while also noting an expected acquisition of Amplitude Vascular Systems to close in the second quarter.
Financially, Stryker generated $745 million in adjusted earnings or $1.93 per share from $6.02 billion in sales for the quarter ending March 31, 2026. While the bottom line represented a 13.9% year-over-year increase and the top line grew 2.6%, the unadjusted EPS of $1.93 fell 38 cents short of the analysts' expected $2.98 per share on revenue that came in below the projected $6.33 billion. Stryker also announced organizational restructuring, combining its orthopedic instruments and Mako surgical robotics portfolios into a single Ortho Tech business to better serve orthopedic customers.
Analysts remain largely bullish on the stock despite the miss. BTIG analysts Ryan Zimmerman and Iseult McMahon maintained their Buy rating, arguing that market prices already reflect the risk of recouping lost sales and noting Stryker's strong track record and order book. Similarly, William Blair analysts led by Steven Lichtman kept a positive stance, citing confidence that most lost sales will be recovered through delayed revenue recognition or procedure pushouts, which is consistent with the company reiterating its guidance for 8.0% to 9.5% organic net sales growth and adjusted EPS between $14.90 and $15.10 for 2026.
📉 Q1 results missed consensus expectations due to March cyberattack disruptions.
🛡️ Company maintains full-year guidance despite significant Q1 operational impacts.
💼 Stryker acquires Amplitude Vascular Systems, expected to close in Q2.
🔄 New Ortho Tech business combines instruments and robotics portfolios.
⬇️ Stock fell over 3% as shares priced in recovery risks.
📉 Stryker (NYSE: SYK) reported first-quarter results that missed Wall Street analyst consensus primarily due to the operational disruption caused by an Iran-backed cyberattack in March.
📊 For Q1 ending March 31, 2026, Stryker earned $745 million or $1.93 per share from $6.02 billion in sales.
⚠️ The reported earnings were 38 cents below analyst expectations of $2.98 EPS and $6.33 billion in expected revenue.
🛡️ CEO Kevin Lobo stated that while growth was meaningfully impacted by the incident, the company is maintaining its full-year guidance.
💼 Stryker announced it is acquiring Amplitude Vascular Systems, with the deal expected to close in the second quarter.
🔄 The company made organizational changes by creating a new Ortho Tech business combining instruments and Mako surgical robotics portfolios.
🎯 Stryker maintains 2026 guidance for organic net sales growth of 8.0–9.5% and adjusted EPS of $14.90–$15.10.
⬇️ Shares fell over 3% to $302.59 following the earnings release, while the S&P 500 rose slightly by contrast.
📈 Adjusted Q1 EPS of $2.60 excluded one-time items related to the cyberattack remediation and lost sales.
💹 BTIG analysts maintained a Buy rating, suggesting the stock price already reflects the risk of recovering lost sales.
👍 William Blair analysts noted confidence that most lost sales will be recovered through delayed revenue or procedure pushouts this year.
🔍 The cyberattack disrupted Stryker's operations at its Michigan headquarters through early April.
📅 This article was originally published on April 30, 2026, and updated with next-day stock performance data.
Bullish Signals
- Guidance: 8.0-9.5% organic net sales growth and $14.90-$15.10 EPS.
- Profit up 13.9% to $745 million despite top-line pressure.
- Acquiring Amplitude Vascular Systems, expected close in Q2.
- Merging orthopedic instruments with surgical robotics portfolios.
- BTIG maintains Buy rating on SYK recovery potential.
- Experts confident lost sales will be recovered this year.
Risk Factors
- Stryker missed Q1 EPS and sales targets.
- Cyberattack disrupted operations and impacted growth.
- Shares dropped 3% to $302.59 after market close.
- Analysts warn prices already factor in recoupment risks.
Bullish Signals
- Stryker maintained its full-year guidance for organic net sales growth of 8.0–9.5% and adjusted net earnings per diluted share of $14.90–$15.10, signaling strong management confidence despite the cyberattack.
- The bottom line was up 13.9% year-over-year to $745 million, demonstrating underlying profitability even with top-line pressure.
- Stryker recently announced an agreement to acquire Amplitude Vascular Systems, expected to close in the second quarter, providing a significant positive catalyst for growth.
- The new Ortho Tech business combination aligns orthopedic instruments and surgical robotics portfolios, aiming to better serve customers and improve operational efficiency.
- Analysts at BTIG maintain their Buy rating on SYK shares, noting that investors are pricing in the recovery potential given Stryker's strong track record and existing order book.
- Industry experts from William Blair express confidence that most lost sales will be recovered through delayed revenue recognition and procedure pushouts within the current year.
Risk Factors
- Stryker's Q1 earnings report missed Wall Street analyst consensus, recording $2.60 EPS versus the expected $2.98 and $6.020 billion in sales versus an anticipated $6.33 billion.
- A major cyberattack by Iran-backed hackers disrupted Stryker's operations from early March through April, meaningfully impacting growth for the quarter that ended March 31, 2026.
- Shares of SYK dropped more than 3% to $302.59 following the after-market-close earnings release, dragging down the stock despite the S&P 500 rising.
- Despite maintaining full-year guidance, analysts note that share prices have already accounted for the risks associated with the need to recoup lost sales for the remainder of the year.
Sonablate, a medical technology company specializing in high-intensity focused ultrasound (HIFU) for non-invasive prostate cancer treatment, announced the appointment of Brad Saar to its Board of Directors on April 30, 2026. Saar, formerly the President of Stryker’s Medical Division, brings over 30 years of global medical technology leadership experience to the company. During his tenure at Stryker, he oversaw a multibillion-dollar business that achieved sustained double-digit growth and completed 15 acquisitions totaling $7.4 billion while driving global manufacturing expansion. His expertise is expected to aid Sonablate in expanding international adoption, increasing physician utilization, and advancing its "precision sound medicine" platform, which uses targeted ultrasound energy to treat disease with surgical-level precision while preserving patient function.
Sonablate's HIFU technology was FDA-cleared in the United States for prostate tissue ablation and is utilized as a non-invasive alternative to surgery and radiation by targeting specific prostate tissue without incisions. The company aims to increase adoption across the urology community through growing clinical engagement and physician education, particularly as interest shifts toward focal therapy and outpatient care models. Saar noted that prostate cancer treatment is reaching an inflection point where non-invasive approaches are moving beyond early adoption into broader clinical consideration, driven by a priority to preserve quality of life.
As part of its ongoing growth strategy, Sonablate will participate in upcoming industry meetings this May, including the ASCA + SAMBA 2026 Conference & Expo and the American Urological Association Annual Meeting (AUA2026). At AUA2026, the company plans to host educational sessions on real-world HIFU use, patient selection, and the role of focal therapy in treating both prostate cancer and benign prostatic hyperplasia (BPH). These efforts are supported by initiatives such as the FUSION Global Registry, which aims to generate real-world evidence for validation and adoption. Sonablate CEO Richard Yang stated that with experienced leadership like Saar's and growing clinical interest, the company is well-positioned to scale globally and advance precision sound medicine as a foundational approach to treating prostate disease.
Sonablate positions itself as a global leader in non-invasive, focused ultrasound technologies, with its Sonablate® HIFU system having received regulatory approvals in more than 50 countries worldwide. The addition of Saar to the board reflects the company's continued focus on supporting the evolution of prostate cancer treatment toward precise, non-invasive, and function-preserving approaches. This strategic move underscores Sonablate's commitment to positioning precision sound medicine at the forefront of the next generation of urologic care while continuing to build clinical engagement within the medical community.
👤 Sonablate appointed Brad Saar, former Stryker Medical President, to its Board.
💰 Saar oversaw 15 acquisitions totaling $7.4B during his Stryker tenure.
🌍 HIFU technology holds FDA clearance and approvals in over 50 countries globally.
🎯 Focused ultrasound platform prioritizes non-invasive treatment preserving patient function worldwide.
🗓 Company will present at ASCA + SAMBA 2026 and AUA Annual Meeting.
👤 Sonablate appointed Brad Saar, former Stryker Medical Division President, to its Board of Directors.
🏥 Saar brings over 30 years of global medical technology leadership experience from Stryker.
💰 During his tenure at Stryker, he oversaw a multibillion-dollar business with 15 acquisitions totaling $7.4 billion.
🚗 Sonablate's HIFU technology is FDA-cleared in the U.S. for non-invasive prostate tissue ablation without incisions.
🎯 The company's "precision sound medicine" platform aims to preserve patient function while treating disease with surgical-level precision.
📈 Saar expressed that prostate cancer treatment is reaching an inflection point where non-invasive approaches are gaining broader clinical consideration.
🗓️ Sonablate will participate in the ASCA + SAMBA 2026 Conference & Expo and AUA Annual Meeting both in May 2026.
🎤 At AUA2026, Sonablate will host educational sessions on real-world use of HIFU for prostate cancer and benign prostatic hyperplasia (BPH).
🌍 The company's FUSION Global Registry is ongoing to generate real-world evidence supporting the platform's validation and adoption.
🎉 A Women in Focal Therapy Leadership forum will convene during the AUA2026 meeting to advance education and collaboration.
🤝 CEO Richard Yang noted that Sonablate is well-positioned to scale globally with experienced leadership and growing clinical interest.
🌐 Sonablate's HIFU system has received regulatory approvals in more than 50 countries worldwide beyond the United States.
💡 The company focuses on expanding international adoption and increasing physician utilization of the focused ultrasound platform.
🧠 Saar's experience scaling global medtech platforms is expected to support advancing Sonablate’s platform to the next growth phase.
🔒 Both Stryker Medical Division and Sonablate prioritize treatments that aim to preserve quality of life for patients.
Bullish Signals
- Sonablate appointed Brad Saar to its Board of Directors.
- Saar brings 30+ years experience leading $7.4B at Stryker.
- Sonablate's HIFU technology is FDA-cleared and approved in 50+ countries.
- Sonablate plans to attend key industry meetings in May 2026.
- The company will host educational sessions on HIFU applications.
- CEO Yang says Sonablate is well positioned for global growth.
- AUA2026 will include a Women in Focal Therapy Leadership forum.
Risk Factors
- Saar led $7.4B acquisitions at Stryker.
- May pursue aggressive dilutive acquisition strategy.
- FDA clearance limited to US market only.
- Over 50 countries approval implies complex regulatory.
- No financial results, revenue or profit disclosed.
Bullish Signals
- Sonablate announced the appointment of Brad Saar, former President of Stryker's Medical Division, to its Board of Directors to support growth.
- Brad Saar brings more than 30 years of experience in global medical technology leadership and previously delivered sustained double-digit growth while leading 15 acquisitions totaling $7.4 billion at Stryker.
- Sonablate's HIFU technology is FDA-cleared in the United States and has received regulatory approvals in more than 50 countries worldwide.
- The company plans to participate in high-profile industry meetings including the ASCA + SAMBA 2026 Conference & Expo and the American Urological Association Annual Meeting (AUA2026) in May to increase physician adoption and awareness.
- Sonablate will host educational sessions and discussions focused on real-world use of HIFU, patient selection, and its application in both prostate cancer and benign prostatic hyperplasia (BPH).
- CEO Richard Yang stated that with experienced leadership and growing clinical interest, Sonablate is well positioned to scale globally and advance precision sound medicine as a foundational approach to treating prostate disease.
- The company is convening clinical and industry stakeholders during AUA2026, including a Women in Focal Therapy Leadership forum focused on advancing education, collaboration, and leadership.
Risk Factors
- The article highlights Brad Saar's previous experience with acquisitions at Stryker, totaling $7.4 billion across 15 deals, which may suggest Sonablate is likely to pursue a similar aggressive acquisition strategy that could dilute existing shareholders.
- Sonablate relies on FDA clearance for only the United States market and has regulatory approvals in more than 50 countries worldwide, indicating potential dependency on international regulatory pathways that are often slower or more costly to navigate.
- The announcement focuses entirely on Brad Saar joining the board, with no mention of Sonablate's current financial results, revenue growth, or profitability metrics, raising questions about the company's standalone performance without this high-profile appointment.
